查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401936

2030 年免疫學市場預測：按藥物類別、適應症、應用和地區分類的全球分析

Immunology Market Forecasts to 2030 - Global Analysis By Drug Class (Immunosuppressants, Monoclonal Antibody, Fusion Proteins, Polyclonal Antibody and Other Drug Classes), Disease Indication, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球免疫學市場規模為989.3億美元，預計2030年將達到1,842.1億美元，複合年成長率為9.5%。

免疫學是生物醫學醫學的一個分支，專注於免疫系統，即細胞、組織、器官和分子的複雜網路。免疫學是一個充滿活力且快速發展的領域，在醫學有著廣泛的應用，從感染疾病管理到自體自體免疫疾病和癌症的治療。

根據英國免疫學會統計，2018年英國約有40萬人患有類風濕性關節炎。

免疫疾病盛行率增加

遺傳因素和世界人口高齡化在許多免疫疾病的發展中發揮重要作用。暴露於某些環境因素，如感染疾病、污染物和毒素，可能引發或惡化免疫失調。這些疾病在免疫學市場上創造了競爭環境。結果，尋求醫療干預的患者數量增加。因此，免疫疾病的新興市場流行對免疫學市場產生多方面的影響，推動需求、創新和研發投資。

嚴格規定

免疫學市場法規的製定是為了確保免疫疾病相關產品的安全性、有效性和品質。這些法規很複雜，免疫藥物核准的嚴格監管流程可能會延遲開發並增加開發成本。監管障礙可能會限制進入市場的新療法的數量。這可能會進一步阻礙新型免疫療法的開拓並限制整個市場的創新。

生物技術和免疫療法的進展

生物技術和免疫療法的進步正在引入治療各種免疫疾病的新策略。生物技術和免疫療法的進步使得針對免疫疾病根本原因的專門治療方法得以開發。此外，由於技術突破，個體化治療技術也成為可能。除了免疫療法的這些重要發展之外，還有細胞和基因療法。由於這些進步，免疫學市場正在受到個人化醫療策略、標靶藥物和最先進治療的創建的推動。

與生物相似藥的競爭

生物相似藥是生物製藥的低成本替代品，其引入可能會對市場構成威脅。日益激烈的競爭可能會導致原產免疫產品的價格壓力和市場佔有率下降。此外，包括小分子和基因療法在內的替代療法的發展也可能對傳統免疫療法構成威脅。這些新治療方法提供了新的治療選擇，並有可能獲得市場佔有率。

COVID-19 的影響

COVID-19大流行對免疫學市場產生了重大影響。在大流行期間，免疫學研究已活性化，以了解新冠病毒對免疫的影響並解決其嚴重影響。各種 COVID-19 疫苗的成功凸顯了免疫學在應對全球健康危機中的重要性，並可能導致對免疫學研究的投資和興趣增加。此外，新型SARS-CoV-2病毒的出現使免疫學成為人們關注的焦點，並影響了免疫學市場的未來開拓。

單株抗體領域預計將成為預測期內最大的市場

由於其臨床普及和高藥物滲透率，單株抗體部分預計將出現良好的成長。單株抗體是實驗室製造的蛋白質，可與體內的特定標靶（例如抗原）結合。單株抗體可以增強、恢復、修改和模擬免疫系統對不需要的細胞的攻擊。更容易的政府核准和相對較低的風險進一步擴大了這一領域。

類風濕性關節炎領域預計在預測期內複合年成長率最高

由於老年人口的增加和研發的不斷增加，預計類風濕性關節炎領域在預測期內將以最快的複合年成長率成長。類風濕性關節炎是一種影響關節的慢性發炎疾病。類風濕性關節炎是推動免疫學市場的關鍵因素，它專門研究免疫系統失調，導致標靶治療、診斷工具的開拓以及對自體免疫疾病的更深入了解。

佔有率最大的地區：

由於其完善的醫療基礎設施，預計北美在預測期內將佔據最大的市場佔有率。該地區自體自體免疫和慢性發炎疾病的盛行率很高。在競爭激烈的北美市場，許多製藥公司都積極從事免疫學相關藥物的研究和銷售。輝瑞、強生、安進、艾伯維等大公司在這一區域市場表現良好。此外，該地區患者的高診斷率可能支持該領域的擴展。

複合年成長率最高的地區：

由於自體自體免疫疾病的盛行率不斷增加，預計歐洲在預測期內將經歷最高的複合年成長率。該地區的主要企業包括 Genmab、Arctoris、Valo Therapeutics 和 BioNTech。根據倫敦估計，7% 的英國人口，即超過 400 萬人，至少患有一種自體免疫疾病。在該地區，我們也專注於獲得核准並推出治療自體免疫疾病的藥物。因此，消費者健康意識的增強和新冠肺炎 (COVID-19) 疫情正在推動歐洲市場的發展。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球免疫學市場：依藥物類別

  • 介紹
  • 免疫抑制劑
  • 單株抗體
  • 融合蛋白
  • 多克隆抗體
  • 其他藥物類別

第6章全球免疫學市場：依疾病適應症

  • 介紹
  • 斑塊型乾癬
  • 類風濕性關節炎
  • 預防器官排斥
  • 乾癬性關節炎
  • 僵直性脊椎炎
  • 發炎性腸道疾病
  • 其他疾病的適應症

第7章全球免疫學市場：依應用分類

  • 介紹
  • 醫院
  • 診所
  • 癌症研究中心和機構
  • 其他用途

第8章全球免疫學市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Novartis AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Janssen Global Services LLC
  • UCB SA
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Aurobindo Pharma
  • F. Hoffmann-La Roche Limited
  • Astellas Pharma Inc.
  • Merck Sharp & Dohme Corporation
Product Code: SMRC24456

According to Stratistics MRC, the Global Immunology Market is accounted for $98.93 billion in 2023 and is expected to reach $184.21 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Immunology is the branch of biomedical science that focuses on the study of the immune system - the complex network of cells, tissues, organs, and molecules that work together to defend the body against infections and other diseases. Immunology is a dynamic and rapidly evolving field with broad applications in medicine, ranging from infectious disease management to the treatment of autoimmune conditions and cancer.

According to British Society for Immunology, in 2018, around 400,000 people in U.K are suffering with rheumatoid arthritis.

Market Dynamics:

Driver:

Increasing prevalence of immunological disorders

Genetic factors and the aging global population play a significant role in the development of many immunological disorders. Exposure to certain environmental factors, such as infections, pollutants, and toxins, may trigger or exacerbate immunological disorders. These disorders foster a competitive environment within the immunology market. It results in a larger patient population seeking medical intervention. Thereby, the increasing prevalence of immunological disorders creates a multifaceted impact on the immunology market, driving demand, innovation, and investment in research and development.

Restraint:

Strict regulations

Regulations in the immunology market are designed to ensure the safety, efficacy, and quality of products related to immunological disorders. These regulations are complex and stringent regulatory processes for the approval of immunology drugs can result in delays and increased development costs. Regulatory hurdles may limit the number of new therapies entering the market. This could further hinder the development of novel immunological therapies and limit the overall innovation in the market.

Opportunity:

Advancements in biotechnology & immunotherapy

Novel strategies for treating a range of immunological illnesses are being introduced by developments in biotechnology and immunotherapy. They make it possible to create specialised treatments that target the underlying causes of immune diseases. Moreover, personalised treatment techniques are made possible by technological breakthroughs. Alongside these important developments in immunotherapy have been cell and gene treatments. Because of these advances, the immunology market is driven by the creation of personalized medical strategies, targeted medicines, and cutting-edge treatment methods.

Threat:

Competition from biosimilars

The introduction of biosimilars, which are lower-cost alternatives to biologic drugs, can pose a threat to the market. Increased competition may lead to pricing pressures and reduced market share for originator immunology drugs. Further, the development of alternative therapies, including small molecules and gene therapies, may also pose a threat to traditional immunology drugs. These emerging therapies could offer new treatment options and potentially capture market share.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the immunology market. During the pandemic, immunology research was increased to understand the effects of covid on immunity and cope with the severe effects of the same. The success of various COVID-19 vaccines has highlighted the importance of immunology in addressing global health crises, potentially leading to increased investment and interest in immunology research. Also, the emergence of new variants of the SARS-CoV-2 virus has kept the spotlight on immunology, which influenced future developments in immunology market.

The monoclonal antibody segment is expected to be the largest during the forecast period

Themonoclonal antibody segment is estimated to have a lucrative growth, due to the clinical efficiency of the procedure and the high prevalence of drugs. Monoclonal antibodies are proteins made in the laboratory for binding to specific targets in the body, such as antigens. They can enhance, restore, modify, or mimic the immune system's attack on unwanted cells. Their easy government approvals and relatively low levels of risk, is further pushing the segment expansion.

The rheumatoid arthritis segment is expected to have the highest CAGR during the forecast period

The rheumatoid arthritis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the growing geriatric population and rising R&D. Rheumatoid arthritis is a chronic inflammatory disorder that affects joints. Rheumatoid arthritis serves as a key driver for advancements in the immunology market by providing a specific focus on immune system deregulation, leading to the development of targeted therapies, diagnostic tools, and a deeper understanding of autoimmune diseases.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a well-established healthcare infrastructure. The region has the high prevalence of autoimmune diseases and chronic inflammatory conditions. Numerous pharmaceutical firms are actively involved in the research and marketing of immunology medications in the fiercely competitive North American market. Pfizer, Johnson & Johnson, Amgen, AbbVie, and other significant firms are doing well in this region market. Additionally, a greater diagnosis rate among patients in the area is probably going to support the expansion of the sector.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of autoimmune disorders. The region is home for several key players such as Genmab, Arctoris, Valo Therapeutics and BioNTech. Additionally, London estimates 7% of the U.K. population, or over 4 million individuals, have at least one autoimmune disorder. The region is also making efforts to secure approvals and launch drugs targeting autoimmune conditions. Thereon, the European market is driven by growing health-consciousness among consumers and boosted by the COVID-19 pandemic.

Key players in the market:

Some of the key players profiled in the Immunology Market include Novartis AG, Eli Lilly and Company, AbbVie Inc., Janssen Global Services LLC, UCB SA, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, F. Hoffmann-La Roche Limited, Astellas Pharma Inc. and Merck Sharp & Dohme Corporation.

Key Developments:

In March 2023, Eli Lilly and Company received approval from the Indian regulatory agency Directorate General of Commercial Intelligence and Statistics (DGCI). This approval allowed them to launch their drug, Copellor, for the treatment of moderate-to-severe plaque psoriasis and also for psoriatic arthritis.

In March 2022, Pfizer Inc. enhanced its product offering by acquiring Arena Pharmaceuticals, a company dedicated to developing cutting-edge therapies for various immuno-inflammatory diseases.

Drug Classes Covered:

  • Immunosuppressants
  • Monoclonal Antibody
  • Fusion Proteins
  • Polyclonal Antibody
  • Other Drug Classes

Disease Indications Covered:

  • Plaque Psoriasis
  • Rheumatoid Arthritis
  • Prophylaxis of Organ Rejection
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Inflammatory Bowel Disease
  • Other Disease Indications

Applications Covered:

  • Hospital
  • Clinics
  • Cancer Research Centers & Institutions
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immunology Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Immunosuppressants
  • 5.3 Monoclonal Antibody
  • 5.4 Fusion Proteins
  • 5.5 Polyclonal Antibody
  • 5.6 Other Drug Classes

6 Global Immunology Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Plaque Psoriasis
  • 6.3 Rheumatoid Arthritis
  • 6.4 Prophylaxis of Organ Rejection
  • 6.5 Psoriatic Arthritis
  • 6.6 Ankylosing Spondylitis
  • 6.7 Inflammatory Bowel Disease
  • 6.8 Other Disease Indications

7 Global Immunology Market, By Application

  • 7.1 Introduction
  • 7.2 Hospital
  • 7.3 Clinics
  • 7.4 Cancer Research Centers & Institutions
  • 7.5 Other Applications

8 Global Immunology Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Novartis AG
  • 10.2 Eli Lilly and Company
  • 10.3 AbbVie Inc.
  • 10.4 Janssen Global Services LLC
  • 10.5 UCB SA
  • 10.6 Amgen Inc.
  • 10.7 Pfizer Inc.
  • 10.8 Bristol-Myers Squibb Company
  • 10.9 Aurobindo Pharma
  • 10.10 F. Hoffmann-La Roche Limited
  • 10.11 Astellas Pharma Inc.
  • 10.12 Merck Sharp & Dohme Corporation

List of Tables

  • Table 1 Global Immunology Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 4 Global Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 5 Global Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 6 Global Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 7 Global Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 8 Global Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 9 Global Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 10 Global Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 11 Global Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 12 Global Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 13 Global Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 14 Global Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 15 Global Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 16 Global Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 17 Global Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 18 Global Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 19 Global Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 20 Global Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 21 North America Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 23 North America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 24 North America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 25 North America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 26 North America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 27 North America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 28 North America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 29 North America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 30 North America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 31 North America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 32 North America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 33 North America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 34 North America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 35 North America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 36 North America Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 37 North America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 38 North America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 39 North America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 40 North America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 41 Europe Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 43 Europe Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 44 Europe Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 45 Europe Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 46 Europe Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 47 Europe Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 48 Europe Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 49 Europe Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 50 Europe Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 51 Europe Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 52 Europe Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 53 Europe Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 54 Europe Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 55 Europe Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 56 Europe Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 57 Europe Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 58 Europe Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 59 Europe Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 60 Europe Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Asia Pacific Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 63 Asia Pacific Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 64 Asia Pacific Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 65 Asia Pacific Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 66 Asia Pacific Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 67 Asia Pacific Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 68 Asia Pacific Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 69 Asia Pacific Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 70 Asia Pacific Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 71 Asia Pacific Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 72 Asia Pacific Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 73 Asia Pacific Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 74 Asia Pacific Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 75 Asia Pacific Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 76 Asia Pacific Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 77 Asia Pacific Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 78 Asia Pacific Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 79 Asia Pacific Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 80 Asia Pacific Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 81 South America Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 83 South America Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 84 South America Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 85 South America Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 86 South America Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 87 South America Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 88 South America Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 89 South America Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 90 South America Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 91 South America Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 92 South America Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 93 South America Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 94 South America Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 95 South America Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 96 South America Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 97 South America Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 98 South America Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 99 South America Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 100 South America Immunology Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 101 Middle East & Africa Immunology Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Immunology Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 103 Middle East & Africa Immunology Market Outlook, By Immunosuppressants (2021-2030) ($MN)
  • Table 104 Middle East & Africa Immunology Market Outlook, By Monoclonal Antibody (2021-2030) ($MN)
  • Table 105 Middle East & Africa Immunology Market Outlook, By Fusion Proteins (2021-2030) ($MN)
  • Table 106 Middle East & Africa Immunology Market Outlook, By Polyclonal Antibody (2021-2030) ($MN)
  • Table 107 Middle East & Africa Immunology Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 108 Middle East & Africa Immunology Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 109 Middle East & Africa Immunology Market Outlook, By Plaque Psoriasis (2021-2030) ($MN)
  • Table 110 Middle East & Africa Immunology Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 111 Middle East & Africa Immunology Market Outlook, By Prophylaxis of Organ Rejection (2021-2030) ($MN)
  • Table 112 Middle East & Africa Immunology Market Outlook, By Psoriatic Arthritis (2021-2030) ($MN)
  • Table 113 Middle East & Africa Immunology Market Outlook, By Ankylosing Spondylitis (2021-2030) ($MN)
  • Table 114 Middle East & Africa Immunology Market Outlook, By Inflammatory Bowel Disease (2021-2030) ($MN)
  • Table 115 Middle East & Africa Immunology Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 116 Middle East & Africa Immunology Market Outlook, By Application (2021-2030) ($MN)
  • Table 117 Middle East & Africa Immunology Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 118 Middle East & Africa Immunology Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 119 Middle East & Africa Immunology Market Outlook, By Cancer Research Centers & Institutions (2021-2030) ($MN)
  • Table 120 Middle East & Africa Immunology Market Outlook, By Other Applications (2021-2030) ($MN)